YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Coya Therapeutics, Inc. (COYA) is a stock that can certainly grab the attention of many investors, but do its recent return…
By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said it will participate at the D. Boral Capital Global Conference, to be held on May 7, 2026, at The Plaza Hotel in New York City. The company’s President and Executive Chairman, Anil R. Diw…
(RTTNews) - Evotec SE (EVO, EVOTF), a German-based drug discovery and development company, on Tuesday announced that it has proposed the election of Dieter Weinand as Chairman of the Supervisory Board at its Annual General Meeting schedule…
Coya Therapeutics (COYA) announced that it has entered into a definitive securities purchase agreement for the purchase and sale of an aggregate of 2.522M shares of its common stock in a private placement at a price of $4.40 per share. The…
- Dr. Reddy’s Laboratories, Inc., a subsidiary of Coya’s current strategic collaborator, makes a $10 million investment - Greenlight Capital, Coya’s largest institutional shareholder, is the only other investor participating in the offerin…
The ALSTARS Trial is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of COYA 302 in patients with amyotrophic lateral sclerosis (ALS) being conducted at clinical sites in the Un…
By Karen Roman ReAlta Life Sciences, Inc. announced the designation of Howard Berman, Ph.D., as Executive Chairman of its Board of Directors, effective immediately. “His proven track record in advancing innovative immunology-based therapie…
FRANKFURT AM MAIN, Germany, Nov. 20, 2025 /PRNewswire/ -- RoboMarkets continues to enhance its platform, providing traders and investors with advanced tools, free real market data, and zero-commission trading on thousands of global instrum…
HOUSTON, November 12, 2025--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients wi…
Greenlight Capital, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Greenlight Capital funds returned -3.6% in the quarter, net of fees and expenses, compa…
* Coya Therapeutics (NASDAQ:COYA [https://seekingalpha.com/symbol/COYA]) has priced a public offering of 3,636,364 shares at $5.50 each, aiming to raise approximately $20.0 million. * The underwriter has a 30-day option to buy an additiona…
[Firing Neurons] koto_feja/E+ via Getty Images Coya Therapeutics (NASDAQ:COYA [https://seekingalpha.com/symbol/COYA]) surged 17% after hedge fund Greenlight disclosed it's the company's largest holder in its lastest Q3 letter to investors.…
(RTTNews) - Several biotech and medical technology stocks posted notable gains in after-hours trading on Monday, with momentum driven by a mix of earnings optimism, clinical trial progress, and speculative positioning. While some names ral…
PRISM MarketView Q&A Highlights FDA IND Clearance, Partnerships, and 2025 Milestones Across ALS and Neurodegeneration Programs NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView today published a Q&A feature with Arun Swaminatha…
Q&A Highlights FDA IND Clearance, Partnerships, and 2025 Milestones Across ALS and Neurodegeneration Programs NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView today published a Q&A feature with Arun Swaminathan, Chief Executiv…
FDA acceptance enables initiation of a Phase 2 multicenter, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of COYA 302 in patients with ALS HOUSTON, Aug. 25, 2025 /PRNewswire/ -- Coya Therapeutics, Inc.…
* Coya Therapeutics press release [https://seekingalpha.com/pr/20197486-coya-therapeutics-reports-second-quarter-financial-results-and-provides-a-corporate-update] (NASDAQ:COYA [https://seekingalpha.com/symbol/COYA]): Q2 GAAP EPS of -$0.36…
Coya Therapeutics , Inc. (NASDAQ:COYA), a $96 million market cap biotech company, announced Monday that it has resubmitted its Investigational New Drug (IND) application to the U.S. Food and Drug Administration for a planned Phase 2 clinic…
Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading…
BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious vira…
We recently published a list of Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Coya Therapeutics, Inc. (NASDAQ:COYA) stands against other top healthcare stocks t…
For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let’s get some of the bad stuff out of the way first. Biotech stocks – even the establish…
Transformative surfaceome discovery technology enables a comprehensive map of the cancer cell surface to identify a multitude of novel druggable targets. Pipeline programs in Small Cell Lung Cancer and Microsatellite-Stable Colorectal Canc…
Under the Agreement, Dr. Reddy’s will obtain commercialization rights for COYA 302 in the United States, Canada, the European Union and the United Kingdom, for patients with ALS COYA will be responsible for development, including the condu…
Coya Therapeutics, Inc. COYA announced that it has entered into a worldwide agreement with Dr. Reddy’s Laboratories Limited RDY. Per the terms of the agreement, Coya will get the license to develop and commercialize Dr. Reddy’s proposed bi…
COYA 302 is an investigational combination biologic for subcutaneous administration, comprised of COYA 301 and CTLA4-Ig (Abatacept). COYA 302 has a dual mechanism of action intended to suppress the chronic and sustained inflammation underl…